Metamark’s quantitative diagnostic approach detects and account for small regions of molecular cancer cells within an otherwise indolent tumor.
Metamark has also developed prognostic and predictive assays portfolio with has the ability to address the heterogeneous nature of tumors not only between one patient and the next, but also within an individual patient’s tumor.
Definiens Sales & Operations vice president Thomas Colarusso said they believe the Definiens Developer XD and Tissue Studio software will facilitate Metamark to classify tumor heterogeneity of multiplexed tissue stains and derive prognostic and predictive assays.